Provide feedbackProvide feedback

Home :: Women's Health

Treatment with adalimumab may halt general bone loss in patients with RA, research shows

Tuesday, April 29 2008 | Comments
Evidence Grade 4 What's This?

Study data show that treatment with adalimumab may inhibit the progression of general bone loss in patients with rheumatoid arthritis, unlike conventional disease-modifying antirheumatic drug therapy.

Fifty patients with active RA who initiated treatment with adalimumab 40 mg every 2 weeks were included in the prospective, open-label study, the goal of which was to explore the effects of tumor necrosis factor blockade on BMD in patients with RA. The participants were all on a...

Study data show that treatment with adalimumab may inhibit the progression of general bone loss in patients with rheumatoid arthritis, unlike conventional disease-modifying antirheumatic drug therapy.

Fifty patients with active RA who initiated treatment with adalimumab 40 mg every 2 weeks were included in the prospective, open-label study, the goal of which was to explore the effects of tumor necrosis factor blockade on BMD in patients with RA. The participants were all on a stable methotrexate regimen and were permitted to use concomitant prednisone in doses of <=10 mg/day. They also were permitted to continue taking anti-osteoporotic agents.

Bone mineral density (BMD) of the lumbar spine and femur neck was measured before treatment was initiated and 1 year later.

The investigators found that the participants' mean 28-item Disease Activity Score decreased from 5.4 at baseline to 3.6 at 16 weeks and 3.4 at week 52 (P<.001 for both). Additionally, based on European League Against Rheumatism response criteria, there were 23 good, 16 moderate, and 7 nonresponders at week 52.

At baseline, the participants' mean lumbar spine BMD was 0.962 g/cm2 and their mean femoral neck BMD was 0.798 g/cm2. These values did not change significantly after 1 year of adalimumab therapy (0.965 g/cm2 and 0.800 g/cm2, respectively).

Increases in femur neck BMD after 1 year were significantly associated with decreases in serum C-reactive protein levels at week 16 (P=.040). The association between decreases in CRP levels at week 52 and increases in femur neck BMD at that same time point were of borderline significance (P=.052).

The authors noted that the results were limited by the design of the study, which may not have been sufficiently powered to detect changes in BMD. They remarked, however, that inhibition of BMD loss with infliximab has been demonstrated previously in patients with RA or ankylosing spondylitis and that "this is the first study to show progressive general bone loss may also be arrested by adalimumab therapy."

The study was supported by Abbott.

These findings were published online April 13 ahead of print in the Annals of the Rheumatic Diseases by Wijbrandts CA, et al.

Latest News

Short, long sleep duration associated with increased likelihood of type 2 diabetes in middle-aged women Verusmed

Wednesday, April 23 2008 | Comments
Among middle-aged women, those with a self-reported sleep duration of <=6 hours or >=8 hours are more likely to have type 2 diabetes relative to those with a sleep duration of 7 hours, according to results of the Finnish type 2 diabetes (FIN-D2D) survey. However, the survey findings did not reveal a similar association in middle-aged men.

The FIN-D2D survey was conducted in 2004 and 2005 to evaluate the FIN-D2D Project, a community-based diabetes prevention program. Researchers...
Tags: Insomnia


Raloxifene improves hip, spine BMD, reduces risk of vertebral fracture in postmenopausal women with osteoporosis, CKD, researchers report Verusmed

Friday, April 18 2008 | Comments
Evidence Grade 3 What's This?
Treatment with raloxifene appears to increase bone mineral density at both the hip and spine and reduces the risk of vertebral fractures in postmenopausal women with osteoporosis and chronic kidney disease, study data indicate.

Researchers conducted a post hoc analysis of 7,316 postmenopausal women who participated in the randomized, controlled MORE study. These women were stratified by creatinine clearance and randomized to receive raloxifene 60 mg/day, raloxifene 120 mg/d, or...


Researchers find hormone therapy has no effect on incidence, severity of RA in postmenopausal women Verusmed

Monday, March 31 2008 | Comments
Evidence Grade 3 What's This?
The use of hormone replacement therapy in postmenopausal women does not increase the risk of developing rheumatoid arthritis or the severity of existing RA, based on recently published trial results.

To assess the effects of hormone therapy on the incidence and severity of RA in postmenopausal women, researchers examined data for 27,347 participants in the randomized controlled trials of the Women's Health Initiative, which evaluated the effects of unopposed estrogen and estrogen...
Tags: Arthritis


Pregabalin improves pain, sleep disturbance in patients with fibromyalgia, study data indicate Verusmed

Monday, March 03 2008 | Comments
Evidence Grade 2 What's This?
Treatment with pregabalin is efficacious and safe in managing pain associated with fibromyalgia, according to data from a Phase III study supported by Pfizer Inc.

Researchers conducted a double-blind trial in which 748 patients with fibromyalgia were randomized to receive pregabalin 300 mg/day, 450 mg/d, or 600 mg/d, administered in 2 divided doses per day, or placebo for 13 weeks. The first goal of the study was to assess the...